Halozyme reports Q3 non-GAAP EPS 74c, consensus 51c

Reports Q3 revenue $209M, consensus $191.1M. "Our Q3 accomplishments are reflective of the expanded opportunities and capabilities at Halozyme that support an enhanced and extended revenue and earnings growth trajectory. DARZALEX SC and Phesgo have continued to demonstrate strong momentum driving 70% year-over-year royalty revenue growth in the Q3. Our partners also continued to advance their development pipelines with ENHANZE. Our Wave 3 products represent the most near-term opportunities with the potential to launch between 2023 and 2025. We are excited for argenx’s biologics license application to the FDA for efgartigimod SC with ENHANZE for Myasthenia Gravis as well as Roche’s plans for regulatory submissions for Tecentriq SC in the U.S. and EU," said Dr. Helen Torley, president and CEO. "Our leadership in drug delivery technologies and innovative commercial products have augmented our growth initiatives, diversified our revenue streams and extended revenue durability. We look forward to further strengthening our position as the drug delivery partner of choice for pharmaceutical and biotechnology companies with both ENHANZE and our auto-injectors."